Schulhoff & Co. Inc. Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK)

Schulhoff & Co. Inc. grew its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,973 shares of the company’s stock after buying an additional 200 shares during the quarter. Schulhoff & Co. Inc.’s holdings in Merck & Co., Inc. were worth $917,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Simon Quick Advisors LLC increased its position in shares of Merck & Co., Inc. by 86.2% in the fourth quarter. Simon Quick Advisors LLC now owns 15,646 shares of the company’s stock valued at $1,199,000 after buying an additional 7,244 shares in the last quarter. Motco increased its position in shares of Merck & Co., Inc. by 0.5% during the fourth quarter. Motco now owns 189,084 shares of the company’s stock worth $14,491,000 after purchasing an additional 940 shares in the last quarter. Nicolet Advisory Services LLC increased its position in shares of Merck & Co., Inc. by 2.4% during the fourth quarter. Nicolet Advisory Services LLC now owns 9,822 shares of the company’s stock worth $753,000 after purchasing an additional 232 shares in the last quarter. Lloyd Park LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $1,502,000. Finally, Natixis Advisors L.P. increased its position in shares of Merck & Co., Inc. by 15.7% during the fourth quarter. Natixis Advisors L.P. now owns 1,010,111 shares of the company’s stock worth $77,415,000 after purchasing an additional 137,380 shares in the last quarter. Institutional investors and hedge funds own 72.05% of the company’s stock.

Shares of Merck & Co., Inc. stock traded up $0.11 during trading hours on Friday, hitting $88.69. The company’s stock had a trading volume of 15,914,164 shares, compared to its average volume of 10,794,321. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $91.40. The firm has a fifty day moving average of $81.53 and a 200-day moving average of $80.10. The stock has a market cap of $224.19 billion, a price-to-earnings ratio of 15.87, a P/E/G ratio of 1.19 and a beta of 0.45. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.83 by $0.31. The firm had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.24% and a net margin of 26.02%. The company’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.40 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 7.27 earnings per share for the current fiscal year.

MRK has been the subject of several research reports. StockNews.com initiated coverage on Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. JPMorgan Chase & Co. dropped their price target on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, January 28th. Barclays boosted their price target on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Mizuho assumed coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price target for the company. Finally, SVB Leerink lowered their price objective on Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, April 21st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $90.69.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.